Search
Close this search box.

Xembify Receives Expanded Label for PI Patients

The U.S. Food and Drug Administration (FDA) has approved an expanded label for Grifols’ XEMBIFY (20% subcutaneous immune globulin [SCIG]) to include treatment-naïve patients with primary humoral immunodeficiencies (PI).

IVIG May Improve Neurological Symptoms in MIS-C

IVIG May Improve Neurological Symptoms in MIS-C

Recent case series findings, as well as previous studies, show that children with multisystem inflammatory syndrome (MIS-C) who present with signs of active neurological symptoms may show improvement with intravenous immune globulin (IVIG) and corticosteroids.